6 billion oseltamivir columand, Yangzijiang two pharmaceutical enterprises into the Bureau.

Pharmaceutical network August 3, the end of July, Oseltamivir has two well-known pharmaceutical enterprises into the Bureau Yangzijiang, Collon, into the bureau oseltamivir July 31, Collum Pharmaceuticals submitted "Oseltamicap capsule" 4 types of generic drugs, the listing application to obtain CDE contractor, officially reported to the listing.
According to the insight database statistics, oseltamivir capsules have seven companies have submitted applications for listing, dry suspension agent also has seven companies reported to the market, including imported generic drugs.
(Photo Source: Insight Database) On the same day, Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd. launched? Phosphate oseltamwereal particles? Biological equivalence test, with a specification of 25mg.
data show that at present only the East Sunshine Oseltamivir capsule first through the consistency evaluation, and launched the Oseltamivir particle BE test;
Oseltamivir is an antiviral drug used in the treatment of influenza A and B in adults and children aged 1 and over.
the original research manufacturer is Roche, the product name Duffy; And? Conway? Listed sales.
in terms of the final market share, Dongsun medicine as early as 2017 to win the domestic market share of nearly 90%, has been the first through the consistency evaluation.
specific data show that the East Sunshine pharmaceutical market accounted for 93.26 percent, Roche 6.2 percent, Shanghai Sino-Western pharmaceutical industry only 0.54 percent.
at present, the domestic approved production of oseltamivir dosage form for capsules (original research Roche, East Sunshine, Shanghai Pharmaceuticals), particulate spelt (East Sunshine).
the production agent form has capsules, granules, dry suspension agents and oral disintegrating tablets.
new dosage forms on the road, urgently need to release the new amount of minet net data shows that in 2019 in China's public medical institutions terminal chemical drug systemic antiviral drug brand TOP10, East Sunshine drug phosphoric acid oseltamivir particles, oseltamivir capsules ranked first and fourth, market share of 17.45 percent, 7.57 percent, Roche's phosphoric acid oseltamivir capsules ranked 10th, market share of only 1.66 percent.
East Sunshine Drug 2019 report shows that the company's phosphate oseltamivir particle sales reached 3.272 billion yuan, up 164.1% YoY;
actually, Oseltamivir still has a larger market waiting to be excavated.
on the one hand, the East Sunshine Drug Covey remains stable growth, its first quarter report said, Kewei in the context of the outbreak of steady growth, high growth from four aspects: the core varieties of Kewei benefit from influenza factors, is expected to be related to influenza testing and drug awareness, higher growth rate;
on the other hand, the emergence of new dosage forms will also facilitate further sales. Li Sibo, a practicing pharmacist at Liaoxi National Drug Chain Co., Ltd.
, once analyzed that the new dosage form of dry suspension is more convenient to take than capsules and is suitable for patients with difficulty swallowing, such as children and the elderly.
it is understood that oseltamivir capsules are currently used in adults and children over one year of age, influenza A or influenza B treatment, should be aware that should be the first symptoms within 48 hours of the use of drugs.
in addition, it can also be used in adults and adolescents over the age of 13 for the prevention of influenza A and B, for children over one year of age, less than 13 years of age, according to the kilogram weight calculation dose - involving the calculation of the dose, dry suspension agent is relatively better control, is also the advantage of distinguishing from capsules.
judging by the growth rate that Oseltamivir has been showing, it may see sales peak again in the future, spurred by new dosage forms.
this, it's also a sign that from 2015 to 2019, oseltamivir has maintained a market growth rate of more than 50 percent per year, even though it is already a billion varieties.
growth rates from 2015 to 2019 were 54.25%, 70.64%, 75.58% and 111.88%, respectively.
(Picture source: Minet) risk is still as a 6 billion varieties, as the progress of consistency evaluation of pharmaceutical companies continue to advance, the volume of procurement continues to become normal, oseltamivir is also increased risk of collection.
for East Sunshine Pharmaceuticals, which already occupies more than 90% of the country's market, if once into the band procurement model, even if the sharp price reduction to take all the share, small sales increase is difficult to offset the impact of sharp price cuts, the company is difficult to maintain the original profits.
in addition, if once the competition also through the price reduction to take a portion of the share, equivalent to through the volume of price-for-price, from scratch, the fastest speed from the east of the sun medicine to seize the market.
now, Dongsun is also taking steps to reduce its over-reliance on Corvette.
East Sunshine Drug 2019 report shows that the company's research and development pipeline variety, in the anti-viral and diabetes and other fields have layout.
in the anti-viral field, the company has submitted a listing application for imiltavir, which is expected to be approved in 2020. The Volarivir and phosphate imetavir combination, developed by
in collaboration with Taijing Pharmaceuticals, has launched Phase III clinical trials and is expected to be listed in 2020.
at the same time, in the field of endocrinology and metabolism, the company has a complete insulin product line planning, covering the second and third generation of insulin, process mature and stable, is one of the few enterprises in China with the ability to develop a full product line varieties.
Recombinant insulin has filed for listing and is expected to be available in 2020, while insulin glargine and sperm protein recombinant insulin are expected to be available in 2021.
with the company's steady progress in research and development, the future is expected to build new growth points in the field of antiviral and diabetes treatment.
.